Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 0.78 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 0.585 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 0.39 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - glyceryl trinitrate, quantity: 25 mg - drug delivery system, transdermal - excipient ingredients: lactose monohydrate; dimeticone; colloidal anhydrous silica; polyethylene terephthalate; aluminium; ethylene/vinyl acetate copolymer; polyvinyl chloride; trichlorotrifluoroethane; simethicone - indicated for the prevention of chronic stable angina pectoris due to coronary artery disease.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - glyceryl trinitrate, quantity: 50 mg - drug delivery system, transdermal - excipient ingredients: lactose monohydrate; dimeticone; colloidal anhydrous silica; polyethylene terephthalate; aluminium; ethylene/vinyl acetate copolymer; polyvinyl chloride; trichlorotrifluoroethane; simethicone - indicated for the prevention of chronic stable angina pectoris due to coronary artery disease.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 1.56mg equivalent to 100 µg per 24 hours - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 1.56mg equivalent to 100 µg per 24 hours excipient: acrylic adhesive dipropylene glycol oleyl alcohol povidone silicone adhesive - the estradot regimen is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis (see dosage and administration and warnings and precautions).

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 0.585mg equivalent 37.5 µg/24 hours - transdermal patch - 37.5 mcg/24h - active: estradiol hemihydrate 0.585mg equivalent 37.5 µg/24 hours excipient: acrylic adhesive dipropylene glycol oleyl alcohol povidone silicone adhesive - the estradot regimen is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 0.78mg equivalent to 50 µg/24 hours - transdermal patch - 50 mcg/24h - active: estradiol hemihydrate 0.78mg equivalent to 50 µg/24 hours excipient: acrylic adhesive dipropylene glycol oleyl alcohol povidone silicone adhesive - the estradot regimen is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis (see dosage and administration and warnings and precautions).

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 1.17mg equivalent to 75 µg per 24 hours - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 1.17mg equivalent to 75 µg per 24 hours excipient: acrylic adhesive dipropylene glycol oleyl alcohol povidone silicone adhesive - the estradot regimen is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis (see dosage and administration and warnings and precautions).

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

rottapharm ltd - estradiol hemihydrate - transdermal patch - 25 mg/24ho milligram